plinabulin (BPI 2358) / Jiangsu Hengrui Pharma, BeyondSpring  >>  Phase 1
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
plinabulin (BPI 2358) / BeyondSpring
NCT00322608: Study of the Vascular Disrupting Agent NPI-2358 in Patients With Advanced Solid Tumors or Lymphoma

Completed
1
35
US
NPI-2358
Nereus Pharmaceuticals, Inc.
Cancer
09/09
12/09
NCT02812667: Nivolumab in Combination With Plinabulin in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC)

Active, not recruiting
1
18
US
Nivolumab + Plinabulin
Lyudmila Bazhenova, M.D., BeyondSpring Pharmaceuticals Inc.
Non-small Cell Lung Cancer Metastatic
07/22
06/25

Download Options